friends of FSH Research

Funding Research for
FSH Muscular Dystrophy Dots

Search News Items

aTyr Pharma Reports Promising Signals with Resolaris

Press release from aTyr
Reprinted with permission Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com +1-858-223-1163 aTyr Pharma Reports Promising Signals of Clinical … http://fshfriends.org/blog/atyr-pharma-reports-promising-signals-resolaris/

aTyr Pharma ongoing Phase 1b/2 Clinical Trials

aTyr Pharma, a company engaged in the discovery and development of therapeutics to address severe rare diseases, is currently conducting two trials of Resolaris (ATYR1940) in patients with rare myopathies with an immune component.
Reprinted with permission from aTyr Pharma aTyr Pharma, a company engaged in the discovery and development of therapeutics to address severe rare diseases, is currently conduct… http://fshfriends.org/blog/atyr-pharma-ongoing-phase-1b2-clinical-trials/

aTyr announces initial results in FSHD trial

aTyr pharma has encouraging news regarding a possible treatment for FSHD using a novel protein-based biologic drug.
aTyr recently released a press statement reporting their initial results from their FSHD study.  The treatment was developed for use in myopathies with an immune component.  This … http://fshfriends.org/blog/atyr-announces-initial-results-fshd-trial/